Effect of Proliverenol on Liver Fat and Insulin Resistance in Type 2 Diabetes
Key facts
- Where
- Palembang, IndonesiaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 65 years old?
Where in Indonesia
- University of Sriwijaya PalembangPalembang, IndonesiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universitas Sriwijaya
- Trial code
- NCT07928661
- Record updated
- 10 November 2026
- Original description
This study aims to determine whether Proliverenol supplementation can improve liver fat levels and blood sugar control in patients with type 2 diabetes. Participants will be divided into two groups: one group will receive Proliverenol with standar therapy of DM, and the other only receive standar therapy of DM. The study will last for 12 weeks, and participants will undergo blood tests and liver examinations."Read full original descriptionShow less
Open Label Evaluator Blind,The Effect of Proliverenol Supplementation on the Visceral Adiposity Index, HOMA-IR, C-Peptide, and Controlled Attenuation Parameter (CAP) in Patients With Type 2 Diabetes at Dr. Mohammad Hoesin General Hospital in Palembang.
This study aims to determine whether Proliverenol supplementation can improve liver fat levels and blood sugar control in patients with type 2 diabetes. Participants will be divided into two groups: one group will receive Proliverenol with standar therapy of DM, and the other only receive standar therapy of DM. The study will last for 12 weeks, and participants will undergo blood tests and liver examinations."
Inclusion: All patients diagnosed with Type 2 diabetes; VAI values: women > 0.705, men > 1.48, or CAP values ≥ 236; Ages 30-65 years; Receiving standard Type 2 diabetes treatment for at least 3 months with HbA1c levels between 7% and 9.5%; Willing to participate in the study by signing an informed consent form.
Exclusion: Taking long-term steroid medication, either oral or systemic; History of or previous infection with hepatitis B or C; History of or currently suffering from an autoimmune disease; ALT/AST levels > 2x ULN, eGFR < 60, or unstable heart disease; Pregnant or breastfeeding women; Regular alcohol consumption.